Transcatheter Arterial Embolization for the Treatment of Liver Metastases in a Patient with Malignant Pheochromocytoma

  • WATANABE Daisuke
    Department of Medicine, Institute of Clinical Endocrinology, Tokyo Women's Medical University
  • TANABE Akiyo
    Department of Medicine, Institute of Clinical Endocrinology, Tokyo Women's Medical University
  • NARUSE Mitsuhide
    Division of Endocrinology, Clinical Research Institute of Endocrine and Metabolic Diseases, Kyoto Medical Center
  • TSUIKI Mika
    Department of Medicine, Institute of Clinical Endocrinology, Tokyo Women's Medical University
  • TORII Nobuyuki
    Department of Medicine, Institute of Clinical Gastroenterology, Tokyo Women's Medical University
  • NOSHIRO Takao
    Noshiro Clinic
  • TAKANO Kazue
    Department of Medicine, Institute of Clinical Endocrinology, Tokyo Women's Medical University

この論文をさがす

抄録

A 63-year-old male patient was admitted for the treatment of malignant pheochromocytoma with multiple liver metastases. Plasma and urinary levels of catecholamines were elevated. Transcatheter arterial embolization (TAE) with concomitant administration of mitomycin C and gelatin sponge was performed for the treatment of liver metastases. Dose of alpha-1 blocker before TAE was increased to prevent hypertensive crisis during and after TAE. The hepatic metastatic lesion of CT findings was decreased after TAE. Although blood pressure showed a transient hypertension (180/100 mmHg) after every TAE, it returned rapidly to normal. The patient experienced transient abdominal pain, nausea, and loss of appetite after every TAE; however, those symptoms were readily controlled by conventional medications. Slight elevation of liver transaminases was recognized but returned to normal range within 3 weeks. No other major side effects were seen with TAE. While plasma and urinary level of catecholamines were unchanged, plasma chromogranin A (CgA) level was significantly decreased. These results suggest that TAE is a useful treatment for hepatic metastases. Plasma CgA level is a useful marker in the treatment of malignant pheochromocytoma.<br>

収録刊行物

  • Endocrine Journal

    Endocrine Journal 53 (1), 59-66, 2006

    一般社団法人 日本内分泌学会

被引用文献 (2)*注記

もっと見る

参考文献 (40)*注記

もっと見る

詳細情報

問題の指摘

ページトップへ